申请人:BLUEPRINT MEDICINES CORP
公开号:WO2021146370A1
公开(公告)日:2021-07-22
One embodiment of the disclosure is a compound represented by Formula I or a pharmaceutically acceptable salt thereof. The variables in Formula I are defined herein. Compounds of Formula I are selective MAP4K1 inhibitors, which can be used to treat a diseases or disorders in a subject that benefits from control of MAP4K1 activity.
本公开的一种实施例是由化学式I表示的化合物或其药用盐。化学式I中的变量在此定义。化学式I的化合物是选择性MAP4K1抑制剂,可用于治疗需要控制MAP4K1活性的受试者的疾病或疾病。